Located in the US, India and Taiwan, StemCyte has established one of the largest, most ethnically diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1500 cord blood products to over 278 leading worldwide transplant centers in 38 countries and 6 continents.
StemCyte recently participated in a clinical study involving the use of umbilical cord blood to treat thalassemia, a devastating worldwide disease. The promising engraftment and survival rate (89%) results suggest the feasibility of unrelated umbilical cord blood transplantation using StemCyte's proprietary plasma depleted cord blood products to treat children with beta-thalassemia major.Where Can I Donate? Click here to find out.
Related-Donor Cord Blood Donation
Through this program, a baby's umbilical cord blood can be collected and used to treat a biological sibling or parent with a diagnosed disease. Some families were eligible to receive this service for free through a program developed by the Health Resources and Services Administration (HRSA). Although the HRSA program ended on Sep 30, 2011, StemCyte has decided to consider and qualify each case on the basis of need and to continue the program at our expense.